Skip to main content
. 2019 Mar 4;24(9):e930–e942. doi: 10.1634/theoncologist.2018-0411

Figure 3.

image

Tumor size percent change from baseline by study part. (A): Part C: Head and neck squamous cell cancer. (B): Part D: Cholangiocarcinoma (CCA), treated with merestinib and cisplatin. (C): Part E: CCA, treated with merestinib, gemcitabine, and cisplatin. (D): Part F: Gastric and gastroesophageal junction cancer. Patients who had more or fewer target lesions at postbaseline than baseline, or whose target lesions that were assessed at baseline were not all assessed at postbaseline, are excluded from the waterfall plot.